EmpiraMed, Inc.

empiramed.com

EmpiraMed’s innovative Real World Evidence (RWE) technology incentivizes patients and reduces clinic burden to improve the success rate of clinical studies that enhance the value proposition of biopharmaceutical therapies. The EmpiraMedTM PRO PortalTM Software Platform is a patient engagement system that offers unsurpassed user “stickiness” to capture the real-world patient experience. Combining our fully automated study execution rules-engine, novel patient recruitment methods, and true PC/mobile device independence, EmpiraMed delivers the most robust Virtual Trial solution available to minimize patient response burden during non-interventional RWE studies. Observational studies typically suffer from poor patient participation, so our portal includes a ground-breaking Rewards Program that has improved patient engagement to 3X current industry standards. Consequently, our customers have seen dramatic increases in patient participation, compliance, wearable device utilization (Passive Monitoring), and overall study success. To support Post Market Required Phase IV Studies and to offer a more comprehensive view of the patient, EmpiraMed has developed an EHR and claims data integration framework in addition to a unique Patient Medical Records (PMR) to EDC unification system. These powerful tools reduce clinic burden to enhance the success rate of regulatory agency mandated studies. In addition to Observational and Post Market Required Studies, our products also support Rare Disease Registries, Outcomes Based Contracts that go beyond just claims data, and Quality Improvement Intervention Programs to improve medication adherence. EmpiraMed has implemented our technology for many large biopharmaceutical companies including Merck Sharp & Dohme, Biogen, Janssen, Sanofi Genzyme, United Therapeutics, Teva, and Takeda.